RHBC
ZYNE

R.H. Bluestein & Co’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

R.H. Bluestein & Co’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-25,200
Closed -$428K – 344
2017
Q2 		$428K Sell
25,200
-21,650
-46% -$430K 0.02% 155
2017
Q1 		$942K Buy
+46,850
New +$931K 0.06% 82

Other funds holding ZYNE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
FTIOP
Fiduciary Trust International of Pennsylvania Radnor, Pennsylvania $2.14B AUM 3.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

R.H. Bluestein & Co's ZYNE Position: Q3 2017 in Review

R.H. Bluestein & Co sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q3 2017, closing a stake of 25,200 shares — an estimated $428K sold.

R.H. Bluestein & Co first reported a position in ZYNE in Q1 2017 and held it in 2 quarters. The position peaked at $942K in Q1 2017. 67 funds tracked by Wall St. Rank hold ZYNE as of Q3 2017.

  • R.H. Bluestein & Co reported no remaining Zynerba Pharmaceuticals, Inc position as of Q3 2017 after selling out during the quarter.
  • R.H. Bluestein & Co sold 25,200 Zynerba Pharmaceuticals, Inc shares in Q3 2017, an estimated $428K.
  • R.H. Bluestein & Co first reported a position in Zynerba Pharmaceuticals, Inc in Q1 2017 and held it in 2 quarters.
  • R.H. Bluestein & Co's Zynerba Pharmaceuticals, Inc position peaked at $942K in Q1 2017.
  • 67 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q3 2017.

Based on R.H. Bluestein & Co's 13F filing for Q3 2017, filed 13 Nov 2017.